AstraZeneca: lung disease drug gets FDA orphan status
(CercleFinance.com) - AstraZeneca's saracatinib has received orphan drug status from the US Food and Drug Administration as a treatment for diopathic pulmonary fibrosis, a type of lung disease that results in a scarring of the lungs, the company said on Monday.
Idiopathic pulmonary fibrosis is a chronic, progressive, irreversible and usually fatal lung disease, which affects approximately 100,000 people in the US.
On average, patients live between two and five years after diagnosis, given the limited medicines available to treat the disease, AstraZeneca said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Idiopathic pulmonary fibrosis is a chronic, progressive, irreversible and usually fatal lung disease, which affects approximately 100,000 people in the US.
On average, patients live between two and five years after diagnosis, given the limited medicines available to treat the disease, AstraZeneca said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.